MX2023013149A - Anti-il-27 antibodies and uses thereof. - Google Patents

Anti-il-27 antibodies and uses thereof.

Info

Publication number
MX2023013149A
MX2023013149A MX2023013149A MX2023013149A MX2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
relates
ameliorating
symptoms
Prior art date
Application number
MX2023013149A
Other languages
Spanish (es)
Inventor
Benjamin Lee
Robert Ross
Kerry White
Alison O''neill
Lauren Harshman
Jonathan Hill
Jou- Ku CHUNG
Original Assignee
Surface Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Oncology Llc filed Critical Surface Oncology Llc
Publication of MX2023013149A publication Critical patent/MX2023013149A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.
MX2023013149A 2021-05-07 2022-05-06 Anti-il-27 antibodies and uses thereof. MX2023013149A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163185989P 2021-05-07 2021-05-07
US202163203688P 2021-07-28 2021-07-28
US202163277035P 2021-11-08 2021-11-08
PCT/US2022/028189 WO2022236134A1 (en) 2021-05-07 2022-05-06 Anti-il-27 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013149A true MX2023013149A (en) 2023-11-28

Family

ID=81928149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013149A MX2023013149A (en) 2021-05-07 2022-05-06 Anti-il-27 antibodies and uses thereof.

Country Status (10)

Country Link
US (1) US20220389089A1 (en)
EP (1) EP4334348A1 (en)
JP (1) JP2024516970A (en)
KR (1) KR20240005809A (en)
AU (1) AU2022270170A1 (en)
CA (1) CA3215856A1 (en)
IL (1) IL308198A (en)
MX (1) MX2023013149A (en)
TW (1) TW202304981A (en)
WO (1) WO2022236134A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024110405A1 (en) * 2022-11-22 2024-05-30 Institut National de la Santé et de la Recherche Médicale Use of il-27 antagonists for the treatment of ebv-driven b lymphoproliferative diseases

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (en) 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334305D1 (en) 1992-08-21 2010-01-28 Univ Bruxelles Immunoglobulins without light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE219517T1 (en) 1995-08-18 2002-07-15 Morphosys Ag PROTEIN/(POLY)PEPTIDE LIBRARIES
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
WO1997042217A1 (en) 1996-05-06 1997-11-13 The Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
ATE481985T1 (en) 2002-07-03 2010-10-15 Ono Pharmaceutical Co IMMUNOPOTENTATING COMPOSITIONS
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2170959T3 (en) 2007-06-18 2014-03-31 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
HRP20240240T1 (en) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
WO2012097238A2 (en) * 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
BR122022015975B1 (en) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES, KIT FOR THE TREATMENT OF AN INDIVIDUAL AFFLICTED WITH A CANCER, PROCESS FOR MEASURING MEMBRANOUS PD-L1 ON ISOLATED TUMOR CELLS AND USE OF THE ANTIBODY OR A PORTION THAT BIDS TO THE ANTIGEN THEREOF
CA2931641C (en) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016106159A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019235842B2 (en) 2018-03-14 2022-02-03 Surface Oncology, Inc. Antibodies that bind CD39 and uses thereof
WO2021062244A1 (en) * 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3215856A1 (en) 2022-11-10
EP4334348A1 (en) 2024-03-13
US20220389089A1 (en) 2022-12-08
JP2024516970A (en) 2024-04-18
AU2022270170A1 (en) 2023-09-21
TW202304981A (en) 2023-02-01
WO2022236134A1 (en) 2022-11-10
KR20240005809A (en) 2024-01-12
IL308198A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
CR20220363A (en) Substituted tricyclic compounds
MX2021013854A (en) Compounds for treating huntington's disease.
WO2007145941A3 (en) Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
MX2022007276A (en) Treatment of amyotrophic lateral sclerosis and related disorders.
IN2012DN02826A (en)
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
MX2020009879A (en) Anti-il-27 antibodies and uses thereof.
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2022012575A (en) Compounds for treating huntington's disease.
MX2023013149A (en) Anti-il-27 antibodies and uses thereof.
MX2022005903A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate.
MX2021012769A (en) Cd73 blocking antibodies.
MX2022004678A (en) Anti-beta-amyloid antibody for treating alzheimer's disease.
MX2022002418A (en) Compositions and methods of treating vascular diseases.
MX2022001084A (en) Method for treating alzheimer's disease by regulating intestinal microorganisms.
MX2022003719A (en) Anti-il-27 antibodies and uses thereof.
MX2023000499A (en) Inflammatory disease treatment using anti-tissue factor antibodies.
MX2021006242A (en) Capsule formulations.
MX2021008081A (en) Treatment of sjogren's disease with nuclease fusion proteins.
MX2022003845A (en) Medicinal cognitive treatments.
MX2021013910A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma.
WO2023278897A9 (en) Compositions and methods for treating cancers
BR112014014805A2 (en) processes for treating and preventing opioid-induced constipation using oral methylnaltrexone compositions
MX2023000763A (en) Anti-il-36r antibodies for the treatment of neutrophilic dermatoses.
MX2022010513A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase.